CD56(bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MS

OBJECTIVE: To assess the relationship between CD56(bright) natural killer (NK) cells and multiple sclerosis (MS) disease activity in patients with relapsing-remitting MS treated with daclizumab high-yield process (DAC HYP). METHODS: Data were from patients enrolled in a 52-week randomized, double-bl...

Descripción completa

Detalles Bibliográficos
Autores principales: Elkins, J., Sheridan, J., Amaravadi, L., Riester, K., Selmaj, K., Bielekova, B., Parr, E., Giovannoni, G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4309527/
https://www.ncbi.nlm.nih.gov/pubmed/25635261
http://dx.doi.org/10.1212/NXI.0000000000000065

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4309527/
https://www.ncbi.nlm.nih.gov/pubmed/25635261
http://dx.doi.org/10.1212/NXI.0000000000000065

Ejemplares similares